Living in areas with lower COI levels was associated with more severe disease presentation and poorer disease control among patients with cSLE.

DENVER — Neuropsychiatric lupus is “arguably the least understood manifestation” of systemic lupus erythematosus (SLE) in children, with patients facing substantial barriers and experiencing ...

The drug’s safety and pharmacokinetic profiles in pediatric patients were consistent with those in adults with systemic lupus erythematosus (SLE). Benlysta has been approved for use in adult ...

Her current research interests include clinical and translational research in pediatric systemic lupus erythematosus (SLE). She continues fostering her passion for both pediatric rheumatology and ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus ...

Incurable Autoimmune Disease Systemic Lupus Erythematosus (SLE): New Genetic Findings Open Up Perspectives for Future Therapeutic Approaches Jan. 14, 2024 — Systemic lupus erythematosus (SLE ...

Children born to anti-Ro antibody-positive mothers do not exhibit a greater prevalence of allergic, neurodevelopmental, or autoimmune conditions.

Current treatment options for systemic lupus erythematosus (SLE) consists of glucocorticoids, antimalarials, immunosuppressives, and a few biologics, approved or of 'off-label'. Through judicious ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

For treating systemic lupus erythematosus (SLE), the usual recommended ... Benlysta can be used in adults and children ages 5 years and older. Both Saphnelo and Benlysta are biologic drugs.

Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for commissioning under NHSE Specialised Commissioning for Children ...